36147In view of reduced inflation and expenses, will it be right to invest in IT stocks?
Many studies suggest a nasal spray vaccine to be more effective than the other mode of vaccination for Covid-19
Global pharmaceutical companies and research institutes are working tirelessly to produce new vaccines to curb the spread of coronavirus infection. Among such new innovations, is a nasal spray which many studies suggest to be more effective than the other mode of vaccination.
As per WHO notification on May 5, a total of 7 intranasal vaccines are undergoing clinical trials in countries like UK, US, India, China.
NITI Aayog member VK Paul has said that around 216 crore vaccine doses will be made available in the next 5 months in India. He added that around 100 million doses of nasal vaccine (nasal vaccine) can be manufactured by India’s Bharat Biotech.
Bharat Biotech’s BBV154
Bharat Biotech has said that their nasal vaccine will be able to respond to the entry of the BBV154 virus into the immune system and will reduce the risk of infection. This vaccine will be effective in both children and adults. The vaccine is undergoing clinical trial now.
SII’s COVI-VAC
American company Codagenix in association with the Serum Institute of India is developing intranasal vaccine COVI-VAC in India. It will be a one-dose vaccine. The initial phase of the clinical trial of the vaccine is underway and it will be immune to many strains of covid-19.
Canadian Company SanOtize’s nasal spray
SaNOtize’s nasal spray has successfully completed the second phase of clinical trials in the United Kingdom. The company’s co-founder and CSO Chris Miller has told Money 9 that the company is now looking for a partner to tie up in India.
Miller said that just the way sanitizer effectively kills germs and microbes on hands or accessories, the nasal vaccine will eliminate the virus-infected through the nasal route.
AdCOVID
Altimmune is another company that is manufacturing a nasal vaccine AdCOVID. This vaccine is in the first phase of a clinical trial. The company has said that by the second quarter of the year 2021, the results of this trial are expected to come.
Finland’s nasal vaccine
Finland’s Rokote Laboratories is also working on an intranasal vaccine. However, according to some reports, the company is yet to settle on concerns related to private investors and investment.